Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market

JOHANNESBURG, South Africa, November 26 - The 2009 Frost & Sullivan South Africa Company of the Year Award in the
Generic Pharmaceutical Market is presented to Cipla Medpro South Africa
Limited.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

For the Company of the Year Award, the following criteria were used to
benchmark Cipla Medpro's performance against key competitors: growth strategy
and implementation, degree of innovation in business processes, products
and/or technologies and leadership in customer value and market penetration.

"The company's growth strategy is displayed in both its expanding
geographic footprint as well as the diversification of its unique product
mix," notes Frost & Sullivan Research Analyst Jolize Gerber. "The company is
growing its South African business by concentrating its efforts on
establishing a stronger presence in the local market across numerous
therapeutic categories as well as the fast-growing Over The Counter market
and, despite adverse market conditions, has enjoyed a solid recent
performance in the past year."

The company has exhibited continued growth in its existing products and
reveals a strong pipeline of new products. This has given Cipla Medpro a
competitive advantage over other companies in the market leading to it being
the fastest growing pharmaceutical company by value over the past three years
according to IMS statistics.

Cipla Medpro has displayed continued innovation of business processes to
maintain growth in a very competitive and complex market. One example is the
strategic partnership formed with Cipla Ltd in India, which entails a 20 year
supply and manufacturing agreement. This partnership has enabled Cipla Medpro
to gain access to R&D, resources and opportunities as well as the
established, trusted brand name offered by Cipla Ltd.

"Cipla Medpro creates and maintains strong brands by ensuring a robust
pipeline of novel, high potential products, and by providing ongoing
promotions and market support," adds Gerber. "These efforts support Cipla
Medpro in growing its market share in the South African market."

The company enjoys leadership in customer value by offering competitive
pricing of high quality products. It has ensured that its production plant
meets international Pharmaceutical Inspection Convention Standards and the
quality of its products is benchmarked against international standards.

Efficient distribution and ongoing marketing support has ensured that the
Cipla Medpro brand is associated with efficiency and reliability.
Furthermore, Cipla Medpro creates customer value by addressing the key
challenges within the South African market.

"An example of this is its diversification into niche markets, such as
the planned launch of its oncology division in 2010, which will address this
market segment's need for affordable medicines," explains Gerber. "By
supplying pharmaceuticals of the highest quality at affordable prices and
addressing the growing needs of South African healthcare, Cipla Medpro has
gained a competitive advantage."

Jerome Smith, Cipla Medpro South Africa Ltd CEO said he was extremely
proud of Frost & Sullivan's acknowledgment of the company's efforts.

"Our comprehensive portfolio of scientifically advanced medicines, strong
pipeline, swift registrations and numerous first to market launches
including, recently, the first Biosimilar human insulin, are testimony of our
commitment to one guiding ethos, that access to world class, yet affordable
medicines is a right, not a luxury.

"The local pharmaceutical market is a competitive, regulated one however
the growth potential is immense. In 2008, generics accounted for just 28% of
the local Total Private Market value. However the rising costs of living,
coupled with the rising cost of healthcare and the ever increasing burden of
disease, particularly HIV/AIDS in sub-Saharan Africa, is creating higher
demand for generic products. Our partnership with Cipla India as well as our
ability to operate across the supply chain from manufacturing to marketing
and distribution, positions us well to meet this increasing demand."

Frost & Sullivan Best Practices Awards recognise companies in
a variety of regional and global markets for demonstrating outstanding
achievement and superior performance in areas such as leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and measure
performance through in-depth interviews, analysis, and extensive secondary
research in order to identify best practices in the industry.

About Cipla Medpro

Listed on the Johannesburg Securities Exchange, Cipla Medpro South Africa
Ltd is one of South Africa's top five, and fastest growing, pharmaceutical
groups through its subsidiary, Cipla Medpro (Pty) Ltd. The Group's operations
comprise two divisions: Cape Town-based Cipla Medpro, the country's fourth
largest pharmaceutical company and provider of an extensive range of chronic
medicines and OTC (Over the Counter) products to the public and private
sector; and a 4000 m2 PIC/S compliant pharmaceutical manufacturing facility
in Durban, Cipla Medpro Manufacturing (Pty) Ltd. In addition to manufacturing
some of the group's own products, this facility also offers contract
manufacturing solutions to large local and multinational pharmaceutical
companies.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from more than 35 offices on six continents. To join our Growth
Partnership, please visit www.frost.com.

    Contact:
    Catherine Brassell
    Best Practices, Frost & Sullivan
    catherine.brassell@frost.com
    P: +44-207-915-7867

Catherine Brassell of Best Practices, Frost & Sullivan, +44-207-915-7867, catherine.brassell at frost.com